SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Cadila Pharma spreads wings to Rwanda

09 Mar 2011 Evaluate

Ahmedabad-based Cadila Pharmaceuticals Ltd is all set to step into Rwandan soil. CSM Global Pharma, a joint venture between Cadila Pharma and US-based Holtzman Group will invest $65 million to set up a pharmaceutical manufacturing facility in Kigali, Rwanda in association with the Rwandan Development Board (RDB). The plant would manufacture solids, tablets and capsules; liquids, gels, ointments, creams and syrups; biologicals, injectables and vaccines and active pharmaceutical ingredients (APIs). It would be fully operational by 2015.


Cadila already has presence in Africa through a 60:40 joint venture with a local partner Almeta Impex. The joint venture firm called Cadila Pharmaceuticals (Ethiopia) PLC is operational since the last three years and is expected to clock a turnover of Rs 20 crore for the year 2010. Rwanda currently depends on imports to meet its requirement for pharmaceutical products. The CSM Global Pharma plant is likely to improve the country's self-sufficiency in terms of drugs production.


Cadila also has a joint venture with NASDAQ listed company Novavax Inc. USA called CPL Biologicals Pvt Ltd. Cadila holds 80 per cent equity in the JV, while the remaining is with Novavax. The JV is working in the area of development and manufacturing of therapeutic and prophylactic vaccines, biological therapeutics and diagnostics in India. The JVC is in the process of developing novel vaccines based on “Virus Like Particles” (VLP) technology.

Zydus Lifesciences Share Price

939.20 3.20 (0.34%)
16-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1693.15
Dr. Reddys Lab 1221.25
Cipla 1230.75
Zydus Lifesciences 939.20
Lupin 2326.50
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×